Europe — EMA
Olanzapine Clonmel Heathcare
GNH USA supplies Olanzapine Clonmel Heathcare (Olanzapine), an atypical antipsychotic for schizophrenia and bipolar disorder.
Request sourcing
What is Olanzapine?
Olanzapine, the active ingredient in Olanzapine Clonmel Heathcare, is an atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia and bipolar I disorder in adults, helping to control psychotic symptoms and mood swings.
GNH USA supplies Olanzapine Clonmel Heathcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Olanzapine used for?
Olanzapine is an atypical antipsychotic used in the management of major psychiatric disorders.
Schizophrenia: reduces psychotic symptoms and lowers the risk of relapse. Bipolar I disorder (manic or mixed episodes): controls manic symptoms and stabilises mood. Maintenance treatment of bipolar disorder: helps prevent recurrence of mood episodes.
What are the side effects of Olanzapine?
Olanzapine may cause a range of adverse reactions, from mild to severe.
Common Side Effects: - Weight gain - Sedation or drowsiness - Dry mouth - Constipation - Increased appetite - Dizziness
Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis - Severe hyperglycaemia or diabetes mellitus - Seizures - Myocarditis or cardiomyopathy - Tardive dyskinesia
What precautions apply to Olanzapine?
Before initiating therapy, clinicians should consider several safety measures.
Monitor metabolic parameters: regularly assess weight, fasting glucose, and lipid profile. Assess cardiovascular risk: watch for orthostatic hypotension and cardiac effects. Evaluate for suicidal ideation: especially during early treatment phases. Use caution in elderly with dementia: increased mortality has been reported. Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.
What does Olanzapine interact with?
Olanzapine can interact with other medicines, requiring careful management.
Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine) may raise olanzapine levels. - CNS depressants (e.g., benzodiazepines) can enhance sedation. - Anticholinergic agents may worsen constipation.
Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., paroxetine) may modestly increase exposure. - Smoking induces CYP1A2, potentially reducing drug concentrations. - Co‑administration with antihypertensives may increase orthostatic hypotension risk.
